Ignite Creation Date:
2024-05-06 @ 2:03 PM
Last Modification Date:
2024-10-26 @ 1:24 PM
Study NCT ID:
NCT04202692
Status:
COMPLETED
Last Update Posted:
2023-04-12
First Post:
2019-12-12
Brief Title:
Effect of a Combination Oral Formulation of Hyaluronic Acid Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment
Sponsor:
SOFAR SpA
Organization:
SOFAR SpA
Study Overview
Official Title:
Evaluation of the Performance and Safety of an Oral Formulation of Hyaluronic Acid With Chondroitin Sulphate and Magnesium Trisilicate GERDOff Plus in Patients With Gastro-Esophageal Reflux Disease A Double-blind Placebo-controlled Randomized Cross-over Study
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a post-market multi-center double-blind placebo-controlled randomized cross-over study with GERDOff Plus added on top of the current PPI treatment in patients with GERD The aim of the study is to evaluate the performance of GERDOff Plus a class III medical device consisting in a hyaluronic acid chondroitin sulphate and magnesium trisilicate in addition to the PPIs in patients with GERD not fully satisfied with their current treatment with PPIs
Patients will receive either GERDOff Plus or placebo qid for 21 days followed by a wash-out period of 3 weeks After the wash-out period the patients will receive either placebo or GERDOff Plus respectively
Patients will receive either GERDOff Plus or placebo qid for 21 days followed by a wash-out period of 3 weeks After the wash-out period the patients will receive either placebo or GERDOff Plus respectively
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None